We are live on
!
Find out more
ST
Skorpios Trust Portfolio holdings
AUM
$53.2M
1-Year Est. Return
90.96%
This Fund
S&P 500
This Quarter
Est. Return
-5.65%
1 Year Est. Return
+90.96%
3 Year Est. Return
+173.58%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$452M
AUM Growth
–
Cap. Flow
+$455M
Cap. Flow
% of AUM
100.73%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stoke Therapeutics
STOK
|
+$345M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$109M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$1.48M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$203K |
| 5 |
Organon & Co
OGN
|
+$17.3K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.64% |
| 2 | Technology | 0.32% |
| 3 | Miscellaneous | 0.04% |
Similar funds
ACM
QUSVM
CCCPV
SGA
NCFG
E
RPM
ECT
Skorpios Trust's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for Skorpios Trust, which disclosed 5 positions worth $452M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Stoke Therapeutics: 14,443,681 shares worth $347M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, followed by Technology and Miscellaneous.
- Skorpios Trust's largest Q4 2021 buy was Stoke Therapeutics: 14,443,681 shares worth $347M.
- Skorpios Trust's ten largest holdings make up 100% of its $452M portfolio in Q4 2021.
- Skorpios Trust disclosed 5 positions in Q4 2021, its first 13F filing on record.
Based on Skorpios Trust's 13F filing for Q4 2021, filed 27 Jan 2022.